DOCSLIB.ORG

Meeting Program Commercial Support Future Annual As of April 15, 2014 Meetings 74Th Annual Meeting May 6-9, 2015 Hilton Atlanta Atlanta, Georgia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Meeting Program Commercial Support Future Annual As of April 15, 2014 Meetings 74Th Annual Meeting May 6-9, 2015 Hilton Atlanta Atlanta, Georgia Meeting Program CommERCIAL SUPPORT FUTURE ANNUAL As of April 15, 2014 MEETINGS 74th Annual Meeting May 6-9, 2015 Hilton Atlanta Atlanta, Georgia 75th Annual Meeting May 11-14, 2016 MISSION The Westin Kierland Resort & Spa Scottsdale, Arizona To advance and promote the sciences relevant to skin health 76th Annual Meeting and disease through education, April 26 - 29, 2017 advocacy and scholarly exchange Oregon Convention Center of scientific information. Portland, Oregon VISION OFFICERS The SID will be the pre-eminent PRESIDENT Paul R. Bergstresser, MD organization for the science of skin health and diseases. It will be a VICE PRESIDENT leading purveyor of educational Lynn A. Cornelius, MD programming. It will promote a culture of discovery and serve as PRESIDENT-ELEct the premier forum for the exchange S. Wright Caughman, MD of scientific information relating to dermatologic research. It will VICE PRESIDENT-ELEct build cross-disciplinary bridges Alexa B. Kimball, MD/MPH to provide catalytic leadership in IMMEDIatE PAST PRESIDENT attaining intellectual, political, and Thomas S. Kupper, MD financial support for skin-related scientific investigation. The SID will SECREtarY -TREASURER be—and be viewed as—a significant Russell P. Hall, MD force in shaping public policy. As a result of recruiting, nurturing, DEPUTY SECREtarY -TREASURER and mentoring the next generation Alice P. Pentland, MD of scientists, it will be a financially 2014 EXHIBITORS JID EDItor robust and self-sustaining Barbara A. Gilchrest, MD organization. CELLnTEC BoaRD OF DIRECTORS DSM CoRE VALUES Lisa A. Beck, MD • Integrity Innocutis James T. Elder, MD/PhD • Collegiality Genemarkers Janet A. Fairley, MD • Shared beliefs Richard L. Gallo, MD/PhD Metabolon, Inc. Maranke I. Koster, PhD • Innovation Midwest Med Books/Elsevier Inc. Andrew P. Kowalczyk, PhD • Leadership David J. Margolis, MD/PhD National Institute of Arthritis and Anthony E. Oro, MD/PhD Musculoskeletal and Skin Diseases M. Joyce Rico, MD/MBA CoNNECT WITH THE SID! Nature Publishing Group Martin Weinstock, MD/PhD Pfizer, Inc. RESIDENT/POST Doctoral FEllows ZenBio, Inc. Anu Mathur, MD/PhD #SIDABQ2014 Fang Liu, PhD www.sidnet.org Welcome to Albuquerque New for 2014! On behalf of the Society for Investigative Dermatology (SID), we welcome ROUND TABLES you to the 2014 Annual Meeting in Albuquerque, New Mexico. Albuquer- The SID Board of Directors invites que, New Mexico’s economic center, and its state capital, Santa Fe, were you to take part in round table founded by Spanish “conquistadores” beginning in the early 1600’s. They discussions during the Poster encountered Native American villages that had been established hundreds Sessions Thursday, Friday & Saturday. of years earlier. These cultures, which are still thriving in the 21st Century, were the setting for the Experts on selected research topics arrival of the modern atomic age in the 1940’s and integral to present day New Mexico. Two of us will be available for informal (RH and PB) call Los Alamos and Albuquerque our original homes, respectively. We are pleased to discussions as attendees tour the present modern New Mexico as an outstanding place for our research community to share advances in posters. cutaneous biology and dermatology and to expand scientific frontiers. We also invite you to appreciate the unique blend of cultures, the spectacular geography, the many historical sites and of course the FEATURED TOPICS exceptional cuisine that celebrates the Spanish, American Indian and Anglo cultures that still define In-Vivo Imaging New Mexico. Gene Mapping Bioinformatics The SID scientific program incorporates research from multiple specialties and disciplines. We would Patch Clamping Mouse Genetics like to thank the 2013-2014 Committee on Scientific Programs for their dedication in developing an Stem Cell Isolation outstanding program. Trans-epidermal Water Loss Cell Sorting SID COMMITTEE ON SCIENTIFIC PROGRAMS Humanized Mouse Model Co-Chairs Immunophenotyping Jack Arbiser, MD/PhD & Mitchell Denning, PhD Clinical Trial Design Drug Design Committee Members Insilica Drug Discovery Anthony Gaspari, MD, Sam Hwang, MD/PhD, My Mahoney, PhD, Sarah Millar, PhD, Paul T. Nghiem, MD/PhD, Abrar Qureshi, MD/PhD, Nicole Ward, PhD, Victoria P. Werth, MD MINISYMPOSIA MIXERS The overall length of Minisymposia Since its founding in 1937, the SID has been committed to facilitating the careers of young investiga- was shortened to three hours. At tors by providing a dynamic forum in which a diverse group of scientists can interact. We remain fully the end of each Minisymposium, committed to this goal and to offer programming that reaches all members of the dermatology and a 45-minute mixer will be held. cutaneous biology research communities Presenters, moderators and attendees will be able to interact as they enjoy light refreshments We have scheduled a variety of activities to highlight scientific advances made by our community, and snacks. These mixers are and social events that will celebrate our international scientific community and the culture and designed to encourage informal beauty of New Mexico. discussion, mingling and networking among SID meeting attendees. Thank you for your support of the SID and enjoy the meeting. Paul Bergstresser, MD Russell Hall, MD Alice Pentland, MD PRESIDENT SecretarY-TREASURER DEPUTY SecretarY-TREASURER 1 2 3 CME Statement & Objectives The Duke Department/Division of Dermatology presents the 2014 Society for Investigative Dermatology Annual Meeting. Jointly sponsored by: COMMERCIAL SUPPORT STATEMENT FACULTY LISTING DISCLAIMER Commercial Support Acknowledgment: This Activity Medical Director: The information provided at this CME activity CME activity is supported by educational Russell P. Hall, III, MD is for continuing education purposes only and grants. A complete list of supporters will be Chair, Department of Dermatology is not meant to substitute for the independent published in the course syllabus. Duke University Medical Center medical judgment of a healthcare provider relative to diagnostic and treatment options of STATEMENT OF NEED Activity Co-Director: a specific patient’s medical condition. The educational programming of the SID Alice P. Pentland, MD is designed to develop, maintain, and/or Chair, Department of Dermatology INSTRUCTIONS ON HOW TO RECEIVE CREDIT increase the abilities, skills, and professional University of Rochester In order to receive CME credit, participants performance of its target audiences. SID must sign-in to http://continuingeducation. CME activities will: SUMMARY OF FACULTY DISCLOSURE/ dcri.duke.edu/, review the CME information 1) Disseminate updated evidence-based CONFLICT RESOLUTION (accreditation, learning objectives, faculty knowledge of skin biology/disease and appli- Staff and Content Validation Reviewer disclosures, etc.) and attend the CME activ- cations for maintaining health and preventing, Disclosure ity. Participants should also complete the diagnosing, and treating disease in a manner The staff involved with this activity and any activity evaluation form and return it to the that fosters scientific excellence, elevates content validation reviewers of this activity appropriate representative following the CME the standard of care, and meets high ethical have reported no relevant financial relation- activity. Participants should also complete the standards. ships with commercial interests. activity evaluation form and return it to the 2) Provide target audiences with a relevant Society for Investigative Dermatology via fax forum for the exchange of cutting-edge scien- RESOLUTION OF CONFLICTS OF INTEREST to 216.579.9333 or mail to: tific ideas, information, and methodology. In accordance with the ACCME Standards 3) Advance the science involved in basic skin of Commercial Support of CME, the Duke Society for Investigative Dermatology / CME biology and clinical care of patients with skin University School of Medicine will implement 526 Superior Avenue E, Suite 540 disease. mechanisms, prior to the planning and imple- Cleveland, OH 44114 4) Provide exposure to novel science (both mentation of this CME activity, to identify and concepts and methods) which may be relevant resolve conflicts of interest for all individuals ACCREDITATION STATEMENT in the future to understanding and treatment in a position to control content of this CME This activity has been planned and imple- skin disease. activity. mented in accordance with the Essential Ar- eas and Policies of the Accreditation Council TARGET AUDIENCE PLANNING COMMITTEE/FACULTY for Continuing Medical Education through The primary target audiences for SID CME DISCLOSURE the joint sponsorship of the Duke University activities include all of the sectors of the der- See addendum for a list of speakers and/or School of Medicine and the Society for Investi- matology community, consisting of research planning committee members who have in- gative Dermatology. The Duke University investigators, clinicians, research and clinical dicated that they have No relationship(s) with School of Medicine is accredited by the AC- trainees, members of industry, and commu- industry to disclose relative to the content of CME to provide continuing medical education nity advocates for skin health/disease. this CME activity. Please see addendum for for physicians. a list of speakers and/or planning commit- tee members who have indicated they have AMA CREDIT STATEMENT LEARNING OBJECTIVES relationships with industry to disclose. The Duke University School of Medicine
Load more

Recommended publications
  • Download Issue
    Cell Circuitry || Science Teaches English || The Chicken Genome Is Hot || Magnets in Medicine SEPTEMBER 2002 www.hhmi.org/bulletin Leading Doublea Life It’s a stretch, but doctors who work bench to bedside say they wouldn’t do it any other way. FEATURES 14 On Human Terms 24 The Evolutionary War A small—some say too small—group of Efforts to undermine evolution education have physician-scientists believes the best science evolved into a 21st-century marketing cam- requires patient contact. paign that relies on legal acumen, manipulation By Marlene Cimons of scientific literature and grassroots tactics. 20 Engineering the Cell By Trisha Gura Adam Arkin sees the cell as a mechanical system. He hopes to transform molecular 28 Call of the Wild biology into a kind of cellular engineering Could quirky, new animal models help scien- and in the process, learn how to move cells tists learn how to regenerate human limbs or from sickness to health. avert the debilitating effects of a stroke? By M. Mitchell Waldrop By Kathryn Brown 24 In front of a crowd of 1,500, Ohio’s Board of Education heard testimony on whether students should learn about intelligent design in science class. DEPARTMENTS 2 NOTA BENE 33 PERSPECTIVE ulletin Intelligent Design Is a Cop-Out 4 LETTERS September 2002 || Volume 15 Number 3 NEWS AND NOTES HHMI TRUSTEES PRESIDENT’S LETTER 5 JAMES A. BAKER, III, ESQ. 34 Senior Partner, Baker & Botts A Creative Influence In from the Fields ALEXANDER G. BEARN, M.D. Executive Officer, American Philosophical Society 35 Lost on the Tip of the Tongue Adjunct Professor, The Rockefeller University UP FRONT Professor Emeritus of Medicine, Cornell University Medical College 36 Biology by Numbers FRANK WILLIAM GAY 6 Follow the Songbird Former President and Chief Executive Officer, SUMMA Corporation JAMES H.
    [Show full text]
  • Open Full Page
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Michael F. Walsh1, Vivian Y. Chang2, Wendy K. Kohlmann3, Hamish S. Scott4, Christopher Cunniff5, Franck Bourdeaut6, Jan J. Molenaar7, Christopher C. Porter8, John T. Sandlund9, Sharon E. Plon10, Lisa L. Wang10, and Sharon A. Savage11 Abstract DNA repair syndromes are heterogeneous disorders caused by around the world to discuss and develop cancer surveillance pathogenic variants in genes encoding proteins key in DNA guidelines for children with cancer-prone disorders. Herein, replication and/or the cellular response to DNA damage. The we focus on the more common of the rare DNA repair dis- majority of these syndromes are inherited in an autosomal- orders: ataxia telangiectasia, Bloom syndrome, Fanconi ane- recessive manner, but autosomal-dominant and X-linked reces- mia, dyskeratosis congenita, Nijmegen breakage syndrome, sive disorders also exist. The clinical features of patients with DNA Rothmund–Thomson syndrome, and Xeroderma pigmento- repair syndromes are highly varied and dependent on the under- sum. Dedicated syndrome registries and a combination of lying genetic cause. Notably, all patients have elevated risks of basic science and clinical research have led to important in- syndrome-associated cancers, and many of these cancers present sights into the underlying biology of these disorders. Given the in childhood. Although it is clear that the risk of cancer is rarity of these disorders, it is recommended that centralized increased, there are limited data defining the true incidence of centers of excellence be involved directly or through consulta- cancer and almost no evidence-based approaches to cancer tion in caring for patients with heritable DNA repair syn- surveillance in patients with DNA repair disorders.
    [Show full text]
  • P020110307527551165137.Pdf
    CONTENT 1.MESSAGE FROM DIRECTOR …………………………………………………………………………………………………………………………………………………… 03 2.ORGANIZATION STRUCTURE …………………………………………………………………………………………………………………………………………………… 05 3.HIGHLIGHTS OF ACHIEVEMENTS …………………………………………………………………………………………………………………………………………… 06 Coexistence of Conserve and Research----“The Germplasm Bank of Wild Species ” services biodiversity protection and socio-economic development ………………………………………………………………………………………………………………………………………………… 06 The Structure, Activity and New Drug Pre-Clinical Research of Monoterpene Indole Alkaloids ………………………………………… 09 Anti-Cancer Constituents in the Herb Medicine-Shengma (Cimicifuga L) ……………………………………………………………………………… 10 Floristic Study on the Seed Plants of Yaoshan Mountain in Northeast Yunnan …………………………………………………………………… 11 Higher Fungi Resources and Chemical Composition in Alpine and Sub-alpine Regions in Southwest China ……………………… 12 Research Progress on Natural Tobacco Mosaic Virus (TMV) Inhibitors…………………………………………………………………………………… 13 Predicting Global Change through Reconstruction Research of Paleoclimate………………………………………………………………………… 14 Chemical Composition of a traditional Chinese medicine-Swertia mileensis……………………………………………………………………………… 15 Mountain Ecosystem Research has Made New Progress ………………………………………………………………………………………………………… 16 Plant Cyclic Peptide has Made Important Progress ………………………………………………………………………………………………………………… 17 Progresses in Computational Chemistry Research ………………………………………………………………………………………………………………… 18 New Progress in the Total Synthesis of Natural Products ………………………………………………………………………………………………………
    [Show full text]
  • WES Gene Package Multiple Congenital Anomalie.Xlsx
    Whole Exome Sequencing Gene package Multiple congenital anomalie, version 5, 1‐2‐2018 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired‐end sequenced on the Illumina platform (outsourced). The aim is to obtain 8.1 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA‐MEM algorithm (reference: http://bio‐bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A4GALT [Blood group, P1Pk system, P(2) phenotype], 111400 607922 101 100 100 99 [Blood group, P1Pk system, p phenotype], 111400 NOR polyagglutination syndrome, 111400 AAAS Achalasia‐addisonianism‐alacrimia syndrome, 231550 605378 73 100 100 100 AAGAB Keratoderma, palmoplantar,
    [Show full text]
  • 2018) 39: I–Iv © 2018 CPS and SIMM All Rights Reserved 1671-4083/18
    Acta Pharmacologica Sinica (2018) 39: i–iv © 2018 CPS and SIMM All rights reserved 1671-4083/18 www.nature.com/aps Acknowledgements to Reviewers The Editorial Board of the Acta Pharmacologica Sinica wishes to thank the following scientists for their unique contribution to this journal in reviewing the papers from January 1, 2017 to December 31, 2017 (including papers published and rejected). AA, Ji-ye (Nanjing) CHEN, Chung-Ming (Taipei) FAN, Chunling (Baltimore) ALICAN, Inci (Istanbul) CHEN, Chung-Yung (Chung-Li) FAN, Guo-Chang (Cincinnati) ALLOATTI, Giuseppe (Torino) CHEN, Gang (Nanjing) FAN, Li (Beijing) ALOBAID, Abdulaziz S (Riyadh) CHEN, Guo-qiang (Shanghai) FAN, Sai-jun (Tianjin) ALSOUS, Mervat (Amman) CHEN, Jian-guo (Wuhan) FANG, Luo (Hangzhou) AMANI, M (Ardabil) CHEN, Jianxiong (Jackson) FANG, Ma-rong (Hangzhou) AMBROSIO, Santiago (Hospitalet Llobregat) CHEN, Jia-xu (Beijing) FANG, Ping-fei (Changsha) ANDERA, Ladislav (Prague) CHEN, Jun (Shanghai) FEI, Zhou (Xi’an) ANGELONE, Tommaso (Arcavacata di CHEN, Ke-ming (Lanzhou) FENG, Jing (Saint Louis) Rende) CHEN, Lin-Zhi (Ridgefield) FENG, Xiao-ming (Tianjin) ANNAERT, Pieter (Leuven) CHEN, Nai-hong (Beijing) FENG, Zhe (Beijing) ASTOLFI, Andrea (Perugia) CHEN, Si-feng (Shanghai) FENG, Zhong-Ping (Toronto) BAHNA, Sarra G (Hamilton) CHEN, Wen-jone (Taipei) FEO, Francesco (Sassari) BAI, Li-Yuan (Taichung) CHEN, Wen-liang (Guangzhou) FIRTH, Amy (Los Angeles) BAI, Xiao-chun (Guandzhou) CHEN, Xiang-mei (Beijing) FLEIDERVISH, Ilya (Beer-Sheva) BAILEY, Craig (Guelph) CHEN, Xiao-qian (Wuhan)
    [Show full text]
  • Orphanet Report Series Rare Diseases Collection
    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
    [Show full text]
  • Trichothiodystrophy
    Trichothiodystrophy Author: Doctor Alfredo Rossi1 and Doctor C. Cantisani. Creation date: June 2004 Scientific Editor: Prof Antonella Tosti 1Dipartimento di Malattie Cutanee-Veneree Chirurgia Plastica-Ricostruttiva, Università degli studi di Roma “La Sapienza” Abstract Keywords Definition Epidemiology Etiology Clinical description Diagnostic methods Prenatal diagnosis Management References Abstract Trichothiodystrophy (TTD) is a rare autosomal recessive genetic disorder characterized by abnormal synthesis of the sulphur containing keratins and consequently hair dysplasia, associated with numerous symptoms affecting mainly organs derived from the neuroectoderm. This phenotypic aspect is due to mutations in the DNA-dependent ATPase/helicase subunit of TFIIH, XPB and XPD. Abnormalities in excision repair of ultraviolet (UV)-damaged DNA are recognized in about half of the patients. The clinical appearance is characterized by brittle and fragile hair, congenital ichthyosis, nail and dental dysplasias, cataract, progeria-like face, growth and mental retardation. The abnormalities are usually obvious at birth, with variable clinical expression. The variants of TTD, depending on their different associations, are known by the initials BIDS, IBIDS, PIBIDS, SIBIDS, ONMRS, as well as the eponyms of the Pollit, Tay, Sabinas syndromes or Amish brittle hair. The exact prevalence of TTD is unknown, but appears to be rather uncommon. About 20 cases of PIBI(D)S have been reported in the literature. Up to 1991, clinical data of 15 cases with IBIDS were published. Prenatal diagnostic of TTD is available. There is no specific treatment. Keywords Brittle hair, photosensitivity, ichthyosis, BIDS, IBIDS, PIBIDS, SIBIDS, ONMRS, Tay-syndrome Definition tail pattern). They named it Trichothiodystrophy, Trichothiodystrophy (TTD) is a group of rare noticing also an increased Photosensitivity and autosomal recessive disorders with heterogenic Ichthyosis in these patients (PIBIDS).
    [Show full text]
  • Test Catalogue August 2019
    Test Catalogue August 2019 www.centogene.com/catalogue Table of Contents CENTOGENE CLINICAL DIAGNOSTIC PRODUCTS AND SERVICES › Whole Exome Testing 4 › Whole Genome Testing 5 › Genome wide CNV Analysis 5 › Somatic Mutation Analyses 5 › Biomarker Testing, Biochemical Testing 6 › Prenatal Testing 7 › Additional Services 7 › Metabolic Diseases 9 - 21 › Neurological Diseases 23 - 47 › Ophthalmological Diseases 49 - 55 › Ear, Nose and Throat Diseases 57 - 61 › Bone, Skin and Immune Diseases 63 - 73 › Cardiological Diseases 75 - 79 › Vascular Diseases 81 - 82 › Liver, Kidney and Endocrinological Diseases 83 - 89 › Reproductive Genetics 91 › Haematological Diseases 93 - 96 › Malformation and/or Retardation Syndromes 97 - 107 › Oncogenetics 109 - 113 ® › CentoXome - Sequencing targeting exonic regions of ~20.000 genes Test Test name Description code CentoXome® Solo Medical interpretation/report of WES findings for index 50029 CentoXome® Solo - Variants Raw data; fastQ, BAM, Vcf files along with variant annotated file in xls format for index 50028 CentoXome® Solo - with CNV Medical interpretation/report of WES including CNV findings for index 50103 Medical interpretation/report of WES in index, package including genome wide analyses of structural/ CentoXome® Solo - with sWGS 50104 large CNVs through sWGS Medical interpretation/report of WES in index, package including genome wide analyses of structural/ CentoXome® Solo - with aCGH 750k 50122 large CNVs through 750k microarray Medical interpretation/report of WES in index, package including genome
    [Show full text]
  • Ispec2020 Program
    Energy Transition and Energy Internet 9. Technical Program 9.1 Registration and Welcome Reception (Sunday, November 22) Time Schedule Room 10:00-20:00 Registration Hotel Lobby 18:00-20:00 Buffet Dinner Provence Western Restaurant 9.2 Technical Sessions (Monday, November 23) Opening Ceremony Chair: Shujun Lu, Deputy President of CSEE Place: Lily Hall A Time: 09:00-9:30, Monday, November 23 Welcome Speakers: Yinbiao Shu President of Chinese Society for Electrical Engineering Frank Lambert President of IEEE PES Haijian Hu President of State Grid Sichuan Electric Power Company Liangyin Chu Vice President of Sichuan University Ning Hua Senior Director, Asia Pacific Business Operations, IEEE November 23-25, 2020 32 IEEE Sustainable Power & Energy Conference Keynote Session 1 Chair: Chongqing Kang, Director of Electrical Engineering Tsinghua University President of Sichuan Energy Internet Research Institute TsingHua University Place: Lily Hall A Time: 09:30-12:00, Monday, November 23 09:30-09:55 KS-01 Several Key Scientific Issues of Polymer Nanocomposites—High Energy Storage Density Electrolytic Condensers Qingquan Lei Academician of the Chinese Academy of Engineering Professor of Harbin University of Science and Technology 09:55-10:20 KS-02 Integration of Renewables and Grid Reliability Chanan Singh Member of the National Academy of Engineering, IEEE Fellow CSEE foreign association Texas A&M University, USA 10:20-10:45 KS-03 Challenges and Countermeasures of CSG System Characteristics Evolution under Power Electronics Dominated Transmission Grid and High Renewable Energy Penetration Chao Hong Senior Technical Expert of China Southern Power Grid Co., Ltd. Director of Systems Research Institute of SEPRI 10:45-11:10 KS-04 Fast Renewable Resource Control in Future Power Systems Joe H.
    [Show full text]
  • Die Fünf Dynastien Und Zehn Staaten in Chinas 10. Jahrhundert
    In Sven Sellmer and Horst Brinkhaus (eds.), Zeitenwenden: Historische Brüche in asiatischen und afrikanischen Gesellschaften (Hamburg: E.B. Verlag, 2002), 273-290. Problematische Zeiten: Die Fünf Dynastien und Zehn Staaten in Chinas 10. Jahrhundert Johannes L. Kurz Zeitenwenden sind in der kaiserlichen chinesischen Geschichte im wörtlichen Sinne zu verstehen, da jede neue Dynastie den Kalender neuordnete und somit die Zeit. Daneben gab es eine ganze Reihe von weiteren Maßnahmen, die die neue Herrschaft als die einzig richtige und in der legitimen Abfolge der Dynastien stehende beweisen sollte. Dazu gehörte die Bezeichnung für die Dynastie, eine Regierungsdevise, die als Motto für die neue Dynastie galt, und, besonders seit der Tang-Zeit, das Abhalten von Prüfun- gen als wichtiges Auswahlkriterium für zukünftige Beamte. Daneben manifestierte sich eine neue Dynastie durch das Setzen eines neuen Kammertones, das Prägen neuer Mün- zen und die Vereinheit-lichung von Gewichten. Dies alles sollte die Elite wie das Volk gleichermaßen davon überzeugen, daß der neue Herrscher das Mandat des Himmels besaß. Im kaiserlichen China waren legitime Dynastien daran zu erkennen, daß sie zum einen das immer wieder neu zu definierende Territorium des chinesischen Reiches unter ihre Herrschaft brachten, und daß sie sich zum anderen in eine Reihenfolge mit den vor- angegangenen Dynastien bringen ließen. Der Herrscher einer Dynastie belegte seine Herrschaft durch das Mandat des Himmels (tianming 天命), welches er und seine Nach- folger solange behalten durften, wie der Himmel ihnen gewogen war. Ebenso konnte das Mandat des Himmels verloren werden, wenn einzelne Herrscher sich als ungeeignet erwiesen. Dies alles funktionierte allerdings nur solange, wie eine Dynastie auf die nächste folgte, was in China nicht zwangsläufig der Fall war.
    [Show full text]
  • 2007 Keio Medical Science Prize Winner Announcement
    FOR IMMEDIATE RELEASE http://www.keio.ac.jp/ September 26, 2007 2007 Keio Medical Science Prize Winner Announcement Keio University presents the “Keio Medical Science Prize” to researchers in recognition of their outstanding achievements in the fields of medical or life sciences. It is the only prize of its kind to be awarded by a Japanese university. The 12th Keio Medical Science Prize will be awarded to Dr. Brian J. Druker and Dr. Hiroaki Mitsuya. Brian J. Druker, M.D. Investigator, Howard Hughes Medical Institute Director, Oregon Health & Science University Cancer Institute JELD-WEN Chair of Leukemia Research For the development of a molecular-targeted drug for chronic myelogenous leukemia Hiroaki Mitsuya, M.D., Ph.D. Professor, Department of Hematology, Department of Rheumatology and Clinical Immunology, Division of Infections Diseases, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University Chief and Principal Investigator, Experimental Retrovirology Section Center for Cancer Research National Cancer Institute For the development of anti-AIDS drugs Award Ceremony and Commemorative Symposium The award ceremony and a commemorative lecture given by the prize winners will be held on December 4, 2007 and a commemorative symposium will take place on December 5. Both events will be held at the Keio University School of Medicine (Shinanomachi Campus). Please see the contact information below to inquire about interviews or photographs. Attachments : (1) About the Keio University Medical Science Fund (2)2007 Prize Winner: Brian J. Druker（Theme, CV, other information） (3)2007 Prize Winner: Hiroaki Mitsuya（Theme, CV, other information） (4)2007 Keio Medical Science Prize Award Ceremony/Commemorative Lecture/ Commemorative Symposium Inquiries: Keio University Medical Science Fund（Ms.
    [Show full text]
  • Chromosomes in the Clinic: the Visual Localization and Analysis of Genetic Disease in the Human Genome
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2013 Chromosomes in the Clinic: The Visual Localization and Analysis of Genetic Disease in the Human Genome Andrew Joseph Hogan University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the History of Science, Technology, and Medicine Commons Recommended Citation Hogan, Andrew Joseph, "Chromosomes in the Clinic: The Visual Localization and Analysis of Genetic Disease in the Human Genome" (2013). Publicly Accessible Penn Dissertations. 873. https://repository.upenn.edu/edissertations/873 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/873 For more information, please contact [email protected]. Chromosomes in the Clinic: The Visual Localization and Analysis of Genetic Disease in the Human Genome Abstract This dissertation examines the visual cultures of postwar biomedicine, with a particular focus on how various techniques, conventions, and professional norms have shaped the `look', classification, diagnosis, and understanding of genetic diseases. Many scholars have previously highlighted the `informational' approaches of postwar genetics, which treat the human genome as an expansive data set comprised of three billion DNA nucleotides. Since the 1950s however, clinicians and genetics researchers have largely interacted with the human genome at the microscopically visible level of chromosomes. Mindful of this, my dissertation examines
    [Show full text]